A failure of this repair pathway that could be expected in cancer patients carrying germline pathogenic mutations in RAD51C and RAD51D sensitizes cancer cells to PARP inhibitors; therefore, patients carrying germline RAD51C and RAD51D mutations may benefit from this therapy [14]. This evidence concerns the gene RAD51C and cancer.